Cargando…
Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration
Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the PANK2 gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disor...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537486/ https://www.ncbi.nlm.nih.gov/pubmed/31205425 http://dx.doi.org/10.1177/1179069519851118 |
_version_ | 1783422022237290496 |
---|---|
author | Jackowski, Suzanne |
author_facet | Jackowski, Suzanne |
author_sort | Jackowski, Suzanne |
collection | PubMed |
description | Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the PANK2 gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disorder is a major challenge in drug discovery. Evaluation of the biochemistry and medicinal chemistry of the proposed therapies reveals potential liabilities among several compounds under consideration for clinical development. |
format | Online Article Text |
id | pubmed-6537486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-65374862019-06-14 Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration Jackowski, Suzanne J Exp Neurosci Commentary Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the PANK2 gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disorder is a major challenge in drug discovery. Evaluation of the biochemistry and medicinal chemistry of the proposed therapies reveals potential liabilities among several compounds under consideration for clinical development. SAGE Publications 2019-05-23 /pmc/articles/PMC6537486/ /pubmed/31205425 http://dx.doi.org/10.1177/1179069519851118 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Commentary Jackowski, Suzanne Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration |
title | Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration |
title_full | Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration |
title_fullStr | Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration |
title_full_unstemmed | Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration |
title_short | Proposed Therapies for Pantothenate-Kinase-Associated Neurodegeneration |
title_sort | proposed therapies for pantothenate-kinase-associated neurodegeneration |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537486/ https://www.ncbi.nlm.nih.gov/pubmed/31205425 http://dx.doi.org/10.1177/1179069519851118 |
work_keys_str_mv | AT jackowskisuzanne proposedtherapiesforpantothenatekinaseassociatedneurodegeneration |